Studies now show a rising prevalence of overweight and obesity among people with type 1 diabetes. In the US, 34% of adults with T1D were overweight and 28% were obese, closely matching the rates seen in people without diabetes. Similar trends have been observed in Belgium, Sweden, Austria, Korea, and Mexico, indicating a global trend.
As obesity rates rise, interest in weight management solutions for T1D has grown. Ozempic (semaglutide), widely known for its weight loss effects, has gained attention for off-label use in obesity treatment. However, its potential benefits and risks for individuals with T1D remain a topic of ongoing research and debate.
This article examines Ozempic’s role in weight management for people with T1D, exploring current research, safety considerations, and expert perspectives.
Are Type 1 Diabetics Usually Overweight?
Type 1 diabetes (T1D) is an autoimmune condition in which the body’s immune system attacks insulin-producing cells in the pancreas.
Insulin allows glucose to enter muscle and fat cells for energy. Without it, glucose builds up in the bloodstream while the body turns to fat and muscle protein for fuel. This process leads to rapid fat loss, making unintentional weight loss a common symptom of undiagnosed T1D.
Historically, this contributed to the belief that people with T1D were generally lean. However, this is no longer the case. Research shows that obesity rates among people with T1D are rising.
Obesity Trends in People with Type 1 Diabetes
Recent studies indicate that obesity is now as common in individuals with T1D as in the general population.
-
- Large registries estimate that 15.3% to 36% of children and adolescents with T1D are overweight or obese.
-
- In Pennsylvania, obesity rates among adults with T1D increased from 32.6% in 2004 to 36.8% in 2018.
-
- In the US and Australia, about 36-37% of adults with T1D are obese.
-
- A long-term study looked at how weight changed over time in people with childhood-onset T1D. After 18 years, the percentage of overweight individuals increased by 47%, and the obesity rate grew sevenfold (from 3.4% to over 22%).
These findings highlight obesity as a growing health concern for people with T1D, prompting healthcare systems to prioritize prevention strategies to mitigate long-term risks. One potential solution being explored is the use of Ozempic (semaglutide) to help with weight loss and metabolic health.
Can Type 1 Diabetics Take Ozempic for Weight Loss?
Ozempic is not FDA-approved for type 1 diabetes. In fact, no GLP-1 receptor agonists (GLP-1RAs), the drug class to which Ozempic belongs, have been approved by the FDA for weight management in people with type 1 diabetes.
However, some healthcare providers are prescribing it off-label. Off-label use means a medication is prescribed for a condition, dosage, or patient group that the FDA (or another regulatory agency) has not officially approved.
GLP-1RA Prescriptions in People with Type 1 Diabetes
Researchers analyzed electronic health records (EHRs) from 2010 to 2023 to track prescribing trends in over 943,000 individuals with T1D in the US.
| Health Profile in T1D Patients | Percentage Among Those Prescribed SGLT2 Inhibitors | Percentage Among Those Prescribed GLP-1RAs |
|---|---|---|
| Heart Failure | 16.6% | 2.8% |
| Chronic Kidney Disease | 26.9% | 15.9% |
| Obesity | 45.7% | 69.4% |
These results suggest that doctors may be prescribing SGLT2 inhibitors to manage heart and kidney complications in T1D patients. In contrast, individuals prescribed GLP-1RAs had a higher rate of obesity, suggesting that GLP-1RAs were primarily used for weight management in this group.
The use of GLP-1RAs among T1D patients also increased from 0.3% in 2010 to 6.6% in 2023. Among these, semaglutide (Ozempic, Wegovy, Rybelsus) saw the most significant increase, from 0.2% in 2018 to 4.4% in 2023. Tirzepatide (Mounjaro, Zepbound), approved in 2022, also gained traction quickly, reaching 1.3% within a year.
So, whether or not someone with T1D can use Ozempic for weight loss depends on their doctor’s discretion. While some are being prescribed Ozempic for weight loss, it remains an off-label use.
Anyone with T1D considering Ozempic should consult their doctor to carefully assess its potential benefits and the risk of complications like diabetic ketoacidosis.
Why is Ozempic Not Approved for Type 1 Diabetics?
Ozempic is not approved for people with T1D, primarily due to its mechanism of action and clinical safety concerns. Here’s why:
1. Risk of Diabetic Ketoacidosis (DKA)
In DKA, ketones build up in the blood, making it too acidic. Ketones are chemicals the body produces when it breaks down fat for energy. This occurs when there isn’t enough insulin to allow glucose to enter cells for fuel.
If left untreated, DKA can lead to dehydration, confusion, vomiting, and even coma. People with T1D are at higher risk because they cannot produce insulin, making them more vulnerable when insulin levels drop too low.
In 2019, health agencies in the UK and US raised concerns about a potential link between GLP-1RAs and DKA. Data from the FDA Adverse Event Reporting System (FAERS) revealed 1,382 cases of DKA and 1,491 cases of ketosis related to GLP-1RA use.
2. Clinical Trial Limitations
The FDA approved Ozempic based on studies demonstrating its ability to regulate blood sugar levels in people with T2D, with weight loss observed as a side effect. However, it has not been extensively studied in individuals with T1D, leaving limited evidence on its safety and effectiveness for this group.
3. Unpredictable Blood Sugar Fluctuations
Many people with T1D use rapid-acting insulin before meals, carefully timing it to match the expected rise in blood sugar after eating. However, Ozempic slows down digestion, meaning food takes longer to be absorbed. This can cause insulin to peak too soon before sugar from food enters the bloodstream, leading to low blood sugar (hypoglycemia).
Later, when the food is finally digested, blood sugar may spike, but there may not be enough insulin left to keep it under control. This can lead to high blood sugar (hyperglycemia).
This mismatch makes it harder for people with type 1 diabetes to maintain stable glucose levels when using Ozempic for weight loss.
What Studies Say About Type 1 Diabetes and Ozempic
A recent study published in Nature Medicine explored whether semaglutide, when used alongside an automated insulin delivery system, could help individuals with T1D improve blood sugar control.
The results showed that individuals taking semaglutide had better blood sugar control than those on a placebo. On average, they spent 4.8% more time within the healthy blood sugar range (3.9-10.0 mmol/L) throughout the day.
Additionally, semaglutide led to significant weight loss. Participants lost an average of 11.7 lbs, equivalent to a 5.1% reduction in body weight.
No cases of severe hypoglycemia or DKA were reported. However, two participants developed euglycemic ketosis, a rare condition in which ketone levels rise without causing acid buildup.
Another study tracked 50 overweight/obese individuals with T1D who used semaglutide for one year. On average, these participants lost 15.9 lbs, translating to a 7.9% decrease in BMI.
Beyond weight loss, semaglutide improved blood sugar control by reducing glucose variability and increasing the time spent within the target blood sugar range. Importantly, there was no increase in hypoglycemic episodes.
Despite these promising findings, both studies were small. Researchers emphasized the need for larger, well-controlled clinical trials to further assess the safety and effectiveness of semaglutide and other GLP-1 receptor agonists in individuals with T1D.
Managing Obesity in People with Type 1 Diabetes
Current guidelines do not provide clear recommendations on the best weight management strategies for individuals with T1D. But, a recent study offers the following recommendations:
1. Diet
Balancing blood sugar levels while making dietary changes is a challenge that adds complexity to weight loss efforts in T1D.
The most effective approach is a personalized diet plan that reduces calories through portion control and healthy eating habits. One major barrier is hypoglycemia, which can trigger overeating and make weight loss more difficult. To prevent this, people with T1D must learn how to adjust their insulin doses in response to dietary changes.
2. Exercise
Exercise is a proven way to help with weight loss. However, for people with T1D, the risk of hypoglycemia during or after exercise, which can even occur overnight, is a significant concern.
To reduce this risk:
Before Exercise
If engaging in low-to-moderate-intensity aerobic exercise for 30-60 minutes while insulin levels are low (such as during fasting), it is recommended to consume 10-15 grams of carbohydrates to help prevent blood sugar from dropping too low.
After Exercise
To reduce the risk of post-exercise hypoglycemia, insulin doses may need to be adjusted:
-
- Long-acting insulin: Reduce by 20-30%
- Bolus insulin (mealtime insulin): Reduce by 50%
- For insulin pump users:
-
-
- Reduce basal insulin (background insulin) by 10-50%
- Reduce bolus insulin by 25-75%
-
This means that people with T1D may need extra carbs before exercise and less insulin afterward to prevent their blood sugar from dropping too low.
3. Bariatric Surgery
Bariatric surgery helps with weight loss by modifying the digestive system, such as reducing stomach size or rerouting the digestive tract. It is usually recommended for people with severe obesity who have not been able to lose weight through diet and exercise alone.
Common types include:
-
- Roux-en-Y Gastric Bypass (RYGB)
- Sleeve Gastrectomy
- Adjustable Gastric Banding (Lap-Band)
- Biliopancreatic Diversion with Duodenal Switch (BPD/DS)
However, similar to the use of Ozempic for weight loss in people with T1D, bariatric surgery also has limited evidence in this group and requires further, larger, well-controlled studies.
Final Thoughts
While type 1 diabetes has traditionally been associated with a lean body type, recent research shows that obesity is becoming increasingly common among individuals with T1D.
Despite this trend, treatments like Ozempic are not FDA-approved for T1D due to concerns about diabetic ketoacidosis and unpredictable blood sugar fluctuations. However, off-label use of Ozempic is rising, particularly among T1D patients with obesity. Early studies suggest that this medication may support weight loss and improve glucose control, but more research is needed to confirm its safety and long-term effects.
Anyone considering medications like Ozempic or making major lifestyle changes should work closely with a healthcare provider to ensure safety and effectiveness.
Frequently Asked Questions
Related Articles
Sources
Wallace, A. S., Chang, A. R., Shin, J., Reider, J., Echouffo-Tcheugui, J. B., Grams, M. E., & Selvin, E. (2022). Obesity and chronic kidney disease in US adults with Type 1 and Type 2 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism, 107(5), 1247–1256. https://doi.org/10.1210/clinem/dgab927
Conway, B., Miller, R. G., Costacou, T., Fried, L., Kelsey, S., Evans, R. W., & Orchard, T. J. (2010). Temporal patterns in overweight and obesity in Type 1 diabetes. Diabetic Medicine, 27(4), 398–404. https://doi.org/10.1111/j.1464-5491.2010.02956.x
Fang, M., Jeon, Y., Echouffo-Tcheugui, J. B., & Selvin, E. (2023). Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes. Annals of internal medicine, 176(3), 427–429. https://doi.org/10.7326/M22-3078
Kueh, M. T. W., Chew, N. W. S., Al-Ozairi, E., & Roux, C. W. L. (2023). The emergence of obesity in type 1 diabetes. International Journal of Obesity, 48(3), 289–301. https://doi.org/10.1038/s41366-023-01429-8
Klobu?ar, S., Detel, D., Igrec, M., Bergo?, A., Raheli?, V., & Raheli?, D. (2024). Overweight and Obesity in Adults with Type 1 Diabetes: A Growing Challenge. Diabetology, 5(3), 234–245. https://doi.org/10.3390/diabetology5030018
Li, P., Li, Z., Staton, E., Umpierrez, G. E., Davis, G., Shao, H., & Pasquel, F. J. (2024). GLP-1 receptor agonist and SGLT2 inhibitor prescribing in people with type 1 diabetes. JAMA, 332(19), 1667. https://doi.org/10.1001/jama.2024.18581
Zhang, J., Ma, Y., Zu, Q., Wang, X., & Zhang, Y. (2024). GLP-1 receptor agonist-induced diabetic ketoacidosis: A case report. Medicine, 103(39), e39799. https://doi.org/10.1097/MD.0000000000039799
Yang, Z., Yu, M., Mei, M., Chen, C., Lv, Y., Xiang, L., & Li, R. (2022). The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system. Nutrition, metabolism, and cardiovascular diseases : NMCD, 32(2), 504–510. https://doi.org/10.1016/j.numecd.2021.10.003
Pasqua, M., Tsoukas, M. A., Kobayati, A., Aboznadah, W., Jafar, A., & Haidar, A. (2025). Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03463-z
Garg, S. K., Kaur, G., Haider, Z., Rodriquez, E., Beatson, C., & Snell-Bergeon, J. (2024). Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes. Diabetes technology & therapeutics, 26(3), 184–189. https://doi.org/10.1089/dia.2023.0490
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., & Bode, B. (2016). Efficacy and safety of liraglutide added to insulin treatment in Type 1 diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care, 39(10), 1702–1710. https://doi.org/10.2337/dc16-0691
Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., & Buse, J. B. (2016). Efficacy and safety of liraglutide added to capped insulin treatment in subjects with Type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care, 39(10), 1693–1701. https://doi.org/10.2337/dc16-0690
